 The FDA has accepted for review CTI BioPharma Corps NASDAQ: CTIC marketing application seeking approval for pacritinib in myelofibrosis patients with severe thrombocytopenia low platelet count. Under the Priority Review, the agencys target action date is November 30, 2021. 